What is the study of pharmacogenomics?
Pharmacogenomics (sometimes called pharmacogenetics) is a field of research that studies how a person’s genes affect how he or she responds to medications. Its long-term goal is to help doctors select the drugs and doses best suited for each person.
What is pharmacogenomics and why is it important?
What is pharmacogenomics? Pharmacogenomics is an important example of the field of precision medicine, which aims to tailor medical treatment to each person or to a group of people. Pharmacogenomics looks at how your DNA affects the way you respond to drugs.
What is the goal of pharmacogenomics?
The goal of pharmacogenomics research is to ensure that doctors implement the findings of precision medicine that aims to tailor treatments based on an individuals genes, lifestyle, environmental factors and other characteristics that represents part of a major initiative.
Who started pharmacogenomics?
Friedrich Vogel
The term pharmacogenetic was first coined in 1959 by Friedrich Vogel of Heidelberg, Germany (although some papers suggest it was 1957 or 1958).
What does the field of pharmacogenomics focus on?
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup.
What are the two goals of pharmacogenetics?
Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients’ genotype, to ensure maximum efficiency with minimal adverse effects.
What pharmacogenetics means?
(FAR-muh-koh-jeh-NEH-tix) The study of how a person’s genes affect the way he or she responds to drugs. Pharmacogenetics is being used to learn ahead of time what the best drug or the best dose of a drug will be for a person. Also called pharmacogenomics.
When was pharmacogenetics invented?
History. Pharmacogenomics was first recognized by Pythagoras around 510 BC when he made a connection between the dangers of fava bean ingestion with hemolytic anemia and oxidative stress. This identification was later validated and attributed to deficiency of G6PD in the 1950s and called favism.
